Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

34.35
Delayed Data
As of 4:02pm ET
 -0.22 / -0.64%
Today’s Change
25.55
Today|||52-Week Range
35.60
+25.73%
Year-to-Date
These 3 Small Biotechs Have a Healthy Shot
3:32pm / TheStreet.com - Paid Partner Content
5 Reasons Why You Should Invest in AstraZeneca (AZN) in 2017
Jun 20 / Zacks.com - Paid Partner Content
Better Days Ahead for the Pharma Sector?
3:20pm / Zacks.com - Paid Partner Content
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
Jun 20 / Zacks.com - Paid Partner Content
Give These 3 Small Biotechs a Shot
11:33am / TheStreet.com - Paid Partner Content
4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio
Jun 20 / Zacks.com - Paid Partner Content
AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use
Jun 27 / Zacks.com - Paid Partner Content
Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why
Jun 16 / Zacks.com - Paid Partner Content
Minerva On Track to Initiate Phase III Schizophrenia Study
Jun 26 / Zacks.com - Paid Partner Content
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
Jun 16 / Zacks.com - Paid Partner Content
Europe Stocks Slip as Economic Data and Politics Return to the Fore
Jun 23 / TheStreet.com - Paid Partner Content
Pharma Stock Roundup: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused
Jun 16 / Zacks.com - Paid Partner Content
Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion
Jun 21 / Zacks.com - Paid Partner Content
Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug
Jun 15 / Zacks.com - Paid Partner Content